B Lymphocyte News and Research

RSS

Type I interferons play crucial role in fending off SARS-CoV-2

Researchers investigated whether individuals with breakthrough infections of COVID-19 pneumonia demonstrated normal antibody responses to vaccinations and whether they harbored type I interferon-neutralizing auto-antibodies.

16 Jun 2022

The severity of COVID-19 compared to seasonal influenza

In a recent study under review at the Archives of Virology journal and currently posted to the Research Square* preprint server, investigators in Israel assessed the disparities and similarities between seasonal influenza and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections.

14 Jun 2022

Risk of severe COVID-19 in adults with immune-mediated inflammatory diseases and those on immune-modifying therapies

Researchers assessed the risk of severe COVID-19 in adults with immune-mediated inflammatory diseases and those on immunomodulatory therapies.

13 Jun 2022

The effect of Omicron breakthrough infection on the magnitude and breadth of serum neutralizing activity and memory B cells among BNT162b2 vaccinees

Researchers evaluated the impact of breakthrough infections with SARS-CoV-2 Omicron BA.1 sublineage on SARS-CoV-2 variants of concern neutralization and memory B lymphocytes formation among BNT162b2 vaccinees.

7 Jun 2022

Study shows the SARS-CoV-2 accessory protein ORF7a inhibits HLA-I surface expression levels in human cells

Researchers identified a single viral gene product, the accessory factor ORF7a, facilitating SARS-CoV-2 immune evasion by downregulating the surface expression of MHC class I molecules.

1 Jun 2022

The effect of CMV serostatus on humoral and cellular measures of vaccine responses after 2 and 3 doses of SARS-CoV-2 mRNA vaccines in older adults

Researchers evaluated the impact of CMV seropositivity on humoral and cellular immune responses generated after double and/or triple mRNA vaccination against SARS-CoV-2 among the elderly.

31 May 2022

New discovery could pave the way for more effective cancer immunotherapy

A type of white blood cell previously known only as a helper in the immune system appears also to be the instigator of the body's defenses against cancerous tumors.

31 May 2022

Hemodialysis patients obtain a robust humoral response from a third dose of the BNT162b2 vaccine, study finds

Researchers assessed the humoral immune responses generated by the third Pfizer-BioNTech BNT162b2 mRNA vaccination against SARS-CoV-2 among hemodialysis patients.

30 May 2022

After SARS-CoV-2 infection, anti-chemokine antibodies correlate with better outcomes

A recent study posted to the bioRxiv* preprint server illustrated that specific chemokine antibodies aid in recognizing severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) convalescent individuals with a desirable disease course.

26 May 2022

Tiny shark-derived antibodies broadly neutralize most SARS-CoV-2 variants

Resarchers discuss the ability of shark-derived antibodies to protect against multiple variants of SARS-CoV-2.

23 May 2022

Can human coronaviruses infect the GI tract?

Researchers review current findings on how human coronaviruses like SARS-CoV-2 might cause GI symptoms.

22 May 2022

Exploring cross-neutralizing anti-SARS-CoV-2 antibody responses among the general population

Researchers performed a molecular analysis of cross-reactive antibodies targeted against the receptor-binding domain of SARS-CoV-2 strains among the general population.

20 May 2022

SARS-CoV-2 Omicron found to be more immune evasive than other variants among mild COVID-19 convalescent patients

Researchers evaluated the humoral and T lymphocyte immune responses against SARS-CoV-2 variants of concern among mild COVID-19 convalescent patients in South Australia.

19 May 2022

Triple BNT162b2 vaccination found to establish long-term T lymphocyte immunity among MDS and CLL patients

In a new study, researchers evaluated the BNT162b2 coronavirus disease 2019 mRNA vaccine (antigen)-specific immune response among myeloid dysplastic syndrome and chronic lymphocytic leukemia patients.

18 May 2022

Combined COVID-19 vaccination regimen found to induce more potent anti-SARS-CoV-2 antibodies

Researchers assessed the vaccine-induced humoral responses against SARS-CoV-2 post four different vaccination regimens comprising homologous and heterologous vaccine doses.

18 May 2022

Impact of cannabidiol on cellular innate immune responses to SARS-CoV-2 genes

A new study published in the journal Life Sciences has focused on examining the effects of ORF8 and ORF10 genes and SARS-CoV-2 Membrane (M) protein on apoptosis.

17 May 2022

A study of SARS-CoV-2-mRNA booster vaccinations in immunocompromised patients

In a recent study published in the journal Frontiers in Immunology, researchers assessed the immune responses induced by vaccination with the messenger ribonucleic acid (mRNA)-1273 vaccine or the BNT162b2 vaccine against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections among immunocompromised individuals.